A Monash University-led trial shows a new medication significantly reduces vasomotor symptoms in women taking oral adjuvant endocrine therapy after breast cancer.

The drug, called Q-122, cut the number and severity of hot flushes and also improved sleep, according to findings published in The Lancet. 

The phase II clinical trial involved 131 women, aged 18-70, taking tamoxifen or an aromatase inhibitor following breast cancer, and experiencing at least 50 self-reported moderate-to-severe vasomotor symptoms per week. 

They were randomised to oral Q-122 100mg, a non-hormonal therapy for the treatment of vasomotor symptoms, or placebo, twice daily for 28 days.